Preclinical characterization of G1T28: A novel CDK4/6 inhibitor for reduction of chemotherapy-induced myelosuppression

Molecular Cancer Therapeutics

Volumn 15, Issue 5, 2016, Pages 783-793

  Bisi, John E ^a   Sorrentino, Jessica A ^a   Roberts, Patrick J ^a   Tavares, Francis X ^b   Strum, Jay C ^a  

^a Research Triangle Park   (United States)

^b Chemogenics Biopharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' [[5 (4 METHYLPIPERAZIN 1 YL)PYRIDIN 2 YL]AMINO] 7',8' DIHYDRO 6'H SPIRO[CYCLOHEXANE 1,9' PYRAZINO[1',2':1,5]PYRROLO[2,3 D]PYRIMIDIN] 6' ONE; CAMPTOTHECIN; CARBOPLATIN; CASPASE 3; CASPASE 7; CYCLIN A; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYCLIN T; CYTOPROTECTIVE AGENT; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; PROTEIN P25; PROTEIN P35; TOPOTECAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTECTIVE AGENT; PROTEIN KINASE INHIBITOR; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; ENZYME ACTIVATION; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BONE MARROW; CELL CYCLE; CHEMISTRY; COMPLICATION; DEFICIENCY; DISEASE MODEL; DNA DAMAGE; DOG; DRUG EFFECTS; GENETICS; METABOLISM; MYELOPOIESIS; NEOPLASMS; PRECLINICAL STUDY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DISEASE MODELS, ANIMAL; DNA DAMAGE; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; HEMATOPOIETIC STEM CELLS; MICE; MYELOPOIESIS; NEOPLASMS; PROTECTIVE AGENTS; PROTEIN KINASE INHIBITORS; RETINOBLASTOMA PROTEIN;

EID: 84969568031     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0775     Document Type: Article

References (31)

1. Sherr CJ.Mammalian G1 cyclins and cell cycle progression. Proc Assoc Am Physicians 1995;107:181-6.
2. Donjerkovic D, Scott DW. Regulation of the G1 phase of the mammalian cell cycle. Cell Res 2000;10:1-16.
3. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015;14:130-46.
4. Johnson SM, Torrice CD, Bell JF, Monahan KB, Jiang Q, Wang Y, et al. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest 2010;120: 2528-36.
5. Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012;104:476-87.
6. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015;524:47-53.
7. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2011;16Suppl 1:61-70.
8. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 2014;111:3110-5.
9. Munger K, Jones DL. Human papillomavirus carcinogenesis: an identity crisis in the retinoblastoma tumor suppressor pathway. J Virol 2015; 89:4708-11.
10. Macleod KF. The RB tumor suppressor: a gatekeeper to hormone independence in prostate cancer? J Clin Invest 2010;120:4179-82.
11. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010;120:4478-92.
12. G1 Therapeutics I. Safety, Pharmacokinetic and pharmacodynamic study of the CDK 4/6 inhibitor G1T28-1. Available from: https://ClinicalTrials. gov/show/NCT02243150
13. G1 Therapeutics I. G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC). Available from: https://ClinicalTrials.gov/show/NCT02499770
14. G1 Therapeutics I. Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy. Available from: https://ClinicalTrials.gov/show/NCT02514447
15. Fabian MA, Biggs WH3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36.
16. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001;10: 699-703.
17. Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005;48:2388-406.
18. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006;25: 5220-7.
19. Foster DA, Yellen P, Xu L, Saqcena M. Regulation of G1 cell cycle progression: distinguishing the restriction point from a nutrient-sensing cell growth checkpoint(s). Genes Cancer 2010;1:1124-31.
20. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11:R77.
21. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010;29:4018-32.
22. Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD,et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 2010;70:3228-38.
23. Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn GP, et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A 2010;107:11501-6.
24. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-5.
25. Cuffe S, Moua T, Summerfield R, Roberts H, Jett J, Shepherd FA. Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers. J Thorac Oncol 2011;6:818-22.
26. National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365: 395-409.
27. Foote M. The importance of planned dose of chemotherapy on time: dowe need to change our clinical practice? Oncologist 1998;3:365-8.
28. Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun 2015;6:6377.
29. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 1995;55:505-9.
30. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004; 430:226-31.
31. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26.